Clinical Trial Update: Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating diazoxide for obesity associated with hypothalamic-pituitary lesions (including craniopharyngiomas) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Craniopharyngioma
• Hypothalamic-pituitary Lesions

Drugs mentioned

• DIAZOXIDE (DIAZOXIDE)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Hypothalamic-pituitary Lesions, Craniopharyngiomas | Phase 3 | Status: COMPLETED